Northern New England

Clinical Oncology Society

2009 Annual Meeting Call for Abstracts

The abstract period has ended. Join us at the meeting for excellent poster and podium presentations.

New Travel and Expense Grant Opportunities CLOSED

Abstract Form

Author Disclosure Form

Sample Abstract

Call for Abstracts Brochure

The Northern New England Clinical Oncology Society seeks abstracts on hematology/oncology topics to share knowledge during the Annual Meeting. Physicians, nurses, mid-level providers, ancillary health care providers (psychologists, physical therapists, etc.), administrators, pharmacists, and post-graduate trainees (fellows, residents) are eligible to submit abstracts.Abstracts previously submitted to ASCO, ASH, etc. are acceptable. NNECOS reserves the right to review and accept submissions.

Abstract Submission Resources

Authors of accepted abstracts will be invited to attend the poster session on the evening of Friday October 23, 2009, offered a discounted meeting registration of $25.00, and be eligible to apply for the new travel and expense grant.
The three best abstracts will be presented orally on Saturday October 24, 2009. The responsible first author will have travel, registration, and lodging covered by NNECOS, and receive a $250 stipend. The submission deadline is 5pm August 31, 2009 (Extended to 5pm September 9th)

Selected Areas/Topics may include:

Novel Clinical Trials/Interventions
Nursing Care
Palliative Care
Business/Administrative issues
Pilot Studies
Best Clinical Practices
Patient and Survivor Issues

Abstracts should be:

250 words or less
10-12 point font
Affiliations clearly listed
Submitted electronically via email to nnecos@comcast.net, following the enclosed template .
Submitted no later than the deadline of 5pm on August 31, 2009 (Extended to September 9th)

1. Abstracts submitted to NNECOS may have been previously presented or published, in whole or in part.

2. Abstracts must be submitted electronically via email to nnecos@comcast.net as an MS Word attachment or in the body of the email. Each First Author will receive an e-mail to verify that NNECOS has received the abstract.

Contact Information
Your name, institution, address, telephone number, fax number, and email address. As the First Author
(presenter), you will receive all future correspondence from NNECOS.

Abstract Title

The title of your abstract in sentence case, capitalizing only the first letter of the first word of the title and any proper nouns or acronyms. Do not use proprietary drug names in the title; use generic drug names instead. Do not refer to study results or conclusions in the title; it should objectively describe the study. NNECOS reserves the right to edit abstract titles to conform to this policy.

Coauthor(s)

The name and institution of each coauthor.

Disclosure Declaration

A separate disclosure form should be filled out by the first author and by each co-authors.

PREPARING AN ABSTRACT

Please make special note of the following when preparing your abstract for submission.

Describe the objectives and results of the research in the abstract so that the NNECOS Abstract Review Committee can evaluate the quality, originality, and completeness of the abstract.
Abstracts will be judged solely on the basis of the data in the submitted abstract.
Statements such as “further data will be available” are discouraged.
Organize the abstract according to four sections, identified by the following headers (in bold): Background, Methods, Results, and Conclusions.
Do not refer to study results or conclusions in the title of the abstract. The title should objectively describe the study.
Do not use proprietary names alone in the title or body of the abstract. If necessary, you may include a proprietary name in parentheses directly after the generic name on first use in the body of the abstract.
Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract. Take particular care to identify complex chemotherapy regimens accurately.
Limit presentation of tables to one, no larger than 3” x 4”

RESPONSIBILITIES OF THE FIRST AUTHOR

The First Author must

· Verify that all coauthors are aware of the contents of the abstract and support its data.

· Agree, on behalf of all coauthors, to transfer copyright to NNECOS for publication in the annual meeting proceedings and on the NNECOS website.

· Agree to deliver an oral presentation if selected (first authors may indicate desire to be considered for poster presentation only)

· Agree to be present during the scheduled time of a Poster Session

· Adhere to the following conflict of interest policy

CONFLICT OF INTEREST POLICY

NNECOS must ensure fair balance, independence, objectivity, and scientific rigor in all of its educational activities through appropriate disclosure of financial interests, among other things. The following interests or relationships must be disclosed: employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration. It is the responsibility of the First Author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships at the time of submission.

2008 Abstract Program

Abstracts Selected for 2008 Annual Meeting

Identifying Priority Needs of Vermont Cancer Survivors Using Focus Groups
D. Cranmer, J. Olson

The prognostic role of PET scanning prior to non-myeloablative allogeneic
transplantation
    C. Engman

Choosing and Implementing an Electronic Health Record
    A. Ireland

Rapid Taper of Immune Suppression Following an Allo Transplant Resulting
in a CR in CLL
    E. Kimtis

The Dartmouth experience in transplantation for Multiple Myeloma: Predictors of disease-free and overall survival
    B. Lipe

Cancer survivors’ lifestyle behaviors and use of support programs and services
    A. Litterini

Immune Mobilization with IL-2 and Growth Factors: Differential In Vivo Effects
of the NKG2D Receptor on CD8+ and CD56+ Effector Cells
    K. Meehan

Building a toolkit to identify risk for hereditary nonpolyposis colorectal cancer
among individuals presenting for screening colonoscopy
    D. Rabinowitz

Evaluation of transitional care summaries
    A. Schaal

Insulin resistance, diabetes mellitus and its association with the risk of breast
cancer.
    G. Torres-Mejía